Table 2. Comparison of clinical and laboratory features between AML patients with and without TP53 mutation.
| Variables | Total (n=500) | TP53 mutated (n=35, 7%) | TP53 wild-type (n=465, 93%) | P-value |
|---|---|---|---|---|
| Sexa | 0.3763 | |||
| Male | 285 | 17 (6) | 268 (94) | |
| Female | 215 | 18 (8.4) | 197 (91.6) | |
| Age (years)b | 51 (15–90) | 67 (30–83) | 50 (15–90) | 0.0003 |
| Lab datab | ||||
| WBC (/μl) | 19 075 (120–627 800) | 3690 (720–178 400) | 22 510 (120–627 800) | <0.0001 |
| Hb (g/dl) | 8 (2.9–16.2) | 7.4 (4.5–12.7) | 8 (2.9–16.2) | 0.1772 |
| Platelet ( × 1000 /μl) | 42 (2–802) | 24 (3–802) | 44 (2–712) | 0.0267 |
| Blast (/μl) | 7401 (0–456 725) | 1145 (0–100 974) | 9744 (0–456 725) | <0.0001 |
| LDH (U/l) | 889 (206–15 000) | 751 (274–15 000) | 860 (206–13 130) | 0.3508 |
| FABa | ||||
| M0 | 10 | 1 (10) | 9 (90) | 0.5193 |
| M1 | 112 | 11 (9.8) | 101 (90.2) | 0.2067 |
| M2 | 171 | 12 (7) | 159 (93) | >0.9999 |
| M3 | 38 | 0 (0) | 38 (100) | 0.0976 |
| M4 | 124 | 5 (4) | 119 (96) | 0.1584 |
| M5 | 24 | 0 (0) | 24 (100) | 0.3994 |
| M6 | 12 | 3 (25) | 9 (75) | 0.0447 |
| Undetermined | 9 | 3 (33.3) | 6 (66.7) | 0.0198 |
| Induction responsec | 363 | 14 | 349 | |
| CR | 284 | 4 (28.6) | 280 (80.2) | <0.0001 |
| PR/refractory | 54 | 7 (50) | 47 (13.5) | 0.0017 |
| Induction death | 25 | 3 (21.4) | 22 (6.3) | 0.0634 |
| Relapsec | 144 | 3 (75) | 141 (50.4) | 0.6225 |
Abbreviations: AML, acute myeloid leukemia; CR, complete remission; FAB, French–American–British; Hb, hemoglobin; LDH, lactate dehydrogenase; PR, partial remission; WBC, white blood cell.
a
Number of patients (%).
b
Median (range).
c
Only 363 patients, including 14 with TP53 mutation and 349 without, who received conventional intensive induction chemotherapy and then consolidation chemotherapy if CR was achieved, as mentioned in the text, were included in the analysis.